SIRT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Li et al. [40] reported that SIRT1 down-regulation improved the acetylation and subsequent transcriptional activity of p53 in CML progenitors, thus enhanced elimination of CML stem cells in combination with imatinib.